Get the Stockscreener App
2.13
5.75%
-0.13
After Hours:
2.14
0.01
+0.47%
Psyence Biomedical Ltd stock is traded at $2.13, with a volume of 264.93K.
It is down -5.75% in the last 24 hours and down -38.44% over the past month.
Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.
See More
Previous Close:
$2.26
Open:
$2.2
24h Volume:
264.93K
Relative Volume:
0.12
Market Cap:
$1.80M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-10.50%
1M Performance:
-38.44%
6M Performance:
-90.53%
1Y Performance:
+0.00%
1-Day Range:
$2.08
$2.3136
1-Week Range:
$2.07
$2.54
52-Week Range:
$1.51
$323.25
Psyence Biomedical Ltd Stock (PBM) Company Profile
Compare PBM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PBM
Psyence Biomedical Ltd
|
2.13 | 1.80M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
399.35 | 102.84B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
702.59 | 77.21B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
619.96 | 37.07B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
236.01 | 30.44B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
112.58 | 26.99B | 3.30B | -501.07M | 1.03B | -2.1146 |
Psyence Biomedical Ltd Stock (PBM) Latest News
Psyence Biomed Announces Closing of $2.0 Million Private Placement - GlobeNewswire
Psyence Biomed (PBM) Raises $2M in Private Placement with Warrant Coverage, Led by H.C. Wainwright - StockTitan
Psyence Biomedical Regains Nasdaq Compliance, Fortifying Market Position - Yahoo Finance
Psyence Biomed announces $2 million private placement By Investing.com - Investing.com Nigeria
PBMPsyence Biomedical Ltd. Common Shares Latest Stock News & Market Updates - StockTitan
Psyence Unveils Private Placement - Baystreet.ca
Psyence Biomed announces $2 million private placement - Investing.com
Psyence Biomed Announces $2.0 Million Private Placement - The Manila Times
Psyence Biomed Secures $2M Private Placement with Strategic Warrant Offering - StockTitan
Psyence Biomedical Achieves Full Nasdaq Compliance, Advances Clinical Trial Plans with $5.6M War Chest - StockTitan
US Stocks To Open Lower As Traders Brace For 'Triple Witching' Hour: Analyst Says End Of The Year Recovery 'Would Not Surprise Anyone' - Benzinga
Psyence Biomedical Signs Exclusive Licensing Agreement with Optimi Health - TipRanks
Psyence Biomedical Advances in Phase IIb Psilocybin Clinical Trial - TipRanks
Psyence Biomed Highlights Recent Progress on Active Phase IIb Clinical Trial - The Manila Times
Optimi Health to Supply GMP-Certified Psilocybin for Psyence Biomed's Phase IIb Palliative Care Trial - Newsfile
Optimi Health Lands Exclusive Psilocybin Supply Deal for Psyence's Groundbreaking Clinical Trials - StockTitan
Psyence Biomedical executes binding agreements with Optimi Health - Yahoo Finance
Psyence Biomedical stock soars on binding agreements with Optimi Health - MSN
Psyence Biomed Executes Binding Agreements with Optimi Health Corp - Marketscreener.com
Psyence Biomed Executes Binding Agreements with Optimi Health Corp. - The Manila Times
Psyence Biomed Secures Landmark Global Psilocybin Supply Deal for Palliative Care Drug Development - StockTitan
Psyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical, to settle outstanding obligations - The Manila Times
Psyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical, to settle - EIN News
Psyence Biomedical Boosts Equity to Meet Nasdaq Rules - TipRanks
Psyence Biomedical Revises Debt-for-Equity Deal - TipRanks
Psyence Biomedical Issues Shareholder Update Highlighting Recent Progress By Investing.com - Investing.com Canada
Psyence Biomed Strengthens Position with Valuable Stake and Trials - TipRanks
Psyence Biomedical Issues Shareholder Update Highlighting Recent Progress - The Manila Times
Psyence Biomedical issues letter to shareholders - TipRanks
Psyence Biomedical Ltd trading halted, news pending - TipRanks
Psyence Biomed granted Nasdaq listing extension By Investing.com - Investing.com Australia
Psyence Biomedical Secures Extension To Meet Nasdaq Compliance Standards - Benzinga
Psyence Biomedical to consolidate shares in bid to keep Nasdaq listing - Green Market Report
Psyence Biomedical gets extension to show compliance with Nasdaq’s listing rules - MSN
Psyence Biomedical Announces Favorable Result of Nasdaq Listing Qualifications Hearing - The Manila Times
Psyence Biomed granted Nasdaq listing extension - Investing.com
Psyence Biomedical Announces Favorable Result Of Nasdaq Listing Qualifications Hearing - XM
Psyence Biomedical Secures Nasdaq Extension, Plans 1-for-75 Share Consolidation | PBM Stock News - StockTitan
Psyence Biomedical fell on 75-to-1 share consolidation and Nasdaq delisting notice - MSN
Psyence Biomed announces share consolidation date - Investing.com India
Psyence Biomedical Announces Effective Date for 1-for-75 Share Consolidation - The Manila Times
Psyence Biomedical Implements 1-for-75 Share Consolidation to Meet Nasdaq Requirements | PBM Stock News - StockTitan
Psyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from Nasdaq - The Manila Times
Psyence Biomedical Shareholders Approve 75:1 Stock Split Amid Nasdaq Compliance Challenge | PBM Stock News - StockTitan
Psyence Biomedical Acquires Stake in PsyLabs - TipRanks
Psyence Biomedical Announces Closing of Previously Announced Acquisition of Psyence Group’s Stake in PsyLabs - GlobeNewswire
Psyence Group Announces Closing of Previously Announced Disposal of its Stake in PsyLabs - Yahoo Finance
Psyence Biomedical Announces Closing of Previously Announced Acquisition of Psyence Group's Stake in PsyLabs - The Manila Times
Psyence Biomedical Ltd Stock (PBM) Financials Data
There is no financial data for Psyence Biomedical Ltd (PBM). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.76%
1.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):